Pfizer Buys Rights to PD-1 & VEGF Inhibitor From China Biotech

Pfizer (PFE) is in-licensing SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, from 3SBio for $1.25 billion upfront, potential milestone payments up to $4.8 billion, and tiered double-digit royalties. SSGJ-707 is currently in development in China for multiple cancers, with a Phase III trial expected this year. This move positions Pfizer to compete with Summit Therapeutics (SMMT), which is also developing a dual PD-1/VEGF inhibitor, ivonescimab, and reflects a growing interest in dual-target therapies for potentially more robust anti-tumor responses compared to single-target PD-1 inhibitors like Merck's Keytruda.

Analysis

Pfizer (PFE) is making a substantial strategic investment to bolster its oncology pipeline by in-licensing global development and commercialization rights (ex-China) for SSGJ-707, a bispecific antibody targeting both PD-1 and VEGF, from Chinese biotech 3SBio. The deal structure involves a significant $1.25 billion upfront payment, potential milestone payments reaching up to $4.8 billion, tiered double-digit royalties, and a $100 million equity investment in 3SBio, underscoring Pfizer's commitment to this late-stage asset, with a Phase III study anticipated to commence this year in China for indications including non-small cell lung cancer (NSCLC). This move is particularly noteworthy as Pfizer's stock has declined 10.2% year-to-date, underperforming the broader industry's 4.0% decrease. The development of SSGJ-707, which aims for a more robust anti-tumor response by targeting two pathways simultaneously, places Pfizer in direct future competition with Summit Therapeutics (SMMT). Summit, in collaboration with Akeso, is developing ivonescimab, a similar dual PD-1/VEGF inhibitor, which is already approved in China for certain NSCLC patients and has reportedly outperformed Merck’s (MRK) blockbuster Keytruda in a Chinese Phase III study. This trend signals growing interest and investment in dual-target immuno-oncology therapies that could potentially disrupt the current standard of care dominated by single-target PD-1/PD-L1 inhibitors like Keytruda.

Key Decisions for Investors

• Pfizer investors should view this as a significant, long-term strategic investment to bolster its oncology pipeline, while remaining cognizant of the substantial future financial commitments and clinical development risks associated with SSGJ-707.
• Closely monitor Phase III trial results for SSGJ-707 and its competitive differentiation against Summit Therapeutics' ivonescimab, as these will be key valuation drivers for PFE and SMMT.
• Recognize the growing competitive threat to Merck's Keytruda from dual PD-1/VEGF inhibitors, which could potentially reshape the treatment landscape for NSCLC and other indications if clinical superiority is established.
• Evaluate the positive validation this deal provides for Summit Therapeutics' approach and asset, potentially impacting its market perception and competitive positioning.